BriaCell Therapeutics (NASDAQ: BCTX, BCTXL; TSX: BCT) has announced progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer.
According to the company, Bria-BRES+ has demonstrated activation of both adaptive and innate immunity, including naïve/resting T cells, dendritic cells, and natural killer cells.
In a statement, Dr. William V. Williams, president and CEO of BriaCell, commented, “Following the encouraging efficacy and tolerability data from BriaCell’s Phase 2 study in metastatic breast cancer, we are expanding our pipeline to include cell-based immunotherapy candidates for gynecologic cancers beginning with ovarian. Bria-OVA+ reflects our broader strategy to build on the Bria-OTS+ platform and advance next-generation personalized immunotherapies for difficult-to-treat cancers and become a leader in women’s health.”
